Mission Bio

In recent years, the cell and gene therapy market has grown at a rapid clip. The momentum is likely to continue. According to Vision Research Reports, the global cell and gene therapy market size could hit around $42.56 billion by 2030, growing at a CAGR of 39% from 2022 to 2030. The burgeoning demand in…

Cell and gene therapies promise to enable broad changes in the healthcare system over the next decade, prompting a growing number of cell and gene therapy companies to join the space. Consider that a cell therapy technique could eliminate the need for immunosuppressive drugs for some organ transplant patients. Cell and gene therapy companies also…

Mission Bio (San Francisco) is a growth-stage company spun out of the microfluidics lab at the University of California San Francisco (UCSF) in 2014. “We have been commercial since late 2017,” said the company’s CEO, Yan Zhang, in a recent interview. Initially focusing on oncology, Mission Bio has cast its gaze across precision medicine to…

Mission Bio has secured $70 million in Series C financing to scale its single-cell multi-omics technology, according to the company. Novo Growth, the growth equity of Novo Holdings, led the round that included new investor Soleus Capital. Previous investors Mayfield, Cota, and Agilent also participated in the financing, which brings the company’s total funding to…